Key insights
- 10x Genomics CEO Serge Saxonov sold $709,057 worth of shares. Part of the sale covered tax obligations, while another portion was executed under a pre-arranged 10b5-1 trading plan. Despite a recent upgrade from William Blair and strong financial performance, InvestingPro analysis suggests the stock is overvalued. The CEO's sale, coupled with valuation concerns, presents a slightly bearish signal.
Serge Saxonov, Chief Executive Officer of 10x Genomics, Inc. (NASDAQ:TXG), sold a total of 28,893 shares of Class A Common Stock for approximately $709,057 across two separate transactions last week. The sales occurred with prices ranging from $24.4415 to $24.7092 per share. The stock currently trades at $25.53, near its 52-week high of $26.45, following a remarkable 197% gain over the past year. According to InvestingPro analysis, the stock appears overvalued at current levels with a Fair Value of $22.11.
On May 22, 2026, Mr. Saxonov disposed of 18,175 shares at a price of $24.4415 per share. These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
Subsequently, on May 26, 2026, an additional 10,718 shares were sold at a weighted average price of $24.7092 per share. This transaction was effected pursuant to a Rule 10b5-1 trading plan, which Mr. Saxonov adopted on November 29, 2025. The shares in this specific transaction were executed in multiple trades at prices ranging from $24.45 to $24.88.
Following these transactions, Mr. Saxonov directly holds 1,138,380 shares of 10x Genomics Class A Common Stock. He also indirectly holds shares through various trusts for which he serves as trustee, including 27 shares through the Andromeda Trust, 213,250 shares through the Y/S Descendants’ Trust, and 71,644 shares through the Y/S Pot Trust. For deeper insights into TXG’s valuation and performance metrics, investors can access comprehensive analysis through the company’s Pro Research Report, available exclusively on InvestingPro.
In other recent news, 10X Genomics has been upgraded by William Blair to an "Outperform" rating, highlighting its role in AI-driven drug discovery. The company has shown strong financial performance, with five consecutive top-line beats and reaching adjusted EBITDA breakeven. Additionally, Bioptimus has launched the Spatial Tissue Embedding Learning Atlas (STELA) in partnership with 10X Genomics and Broad Clinical Labs, aiming to significantly increase the scale of spatial biology data generation.
Meanwhile, Wolfe Research has noted concerns over a potential decline in demand for spatial proteomics following a tweet by Microsoft’s CEO about the GigaTIME AI model. This has contributed to investor apprehension regarding the future of clinical applications in spatialomics. Furthermore, ARK Invest has sold over 473,000 shares of 10X Genomics, indicating a strategic shift towards gene-editing platforms. Lastly, Stifel has raised its price target for 10X Genomics to $25, citing favorable product adoption and a competitive single-cell environment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.